In general, POMC neuron-derived peptides, such as -MSH, can activate the melanocortin-4 receptor (MC4R) in the PVN, which can be inhibited by AgRP released from the AgRP/NPY neurons [16, 17]
Over the course of six clinic-administered sessions, clients typically experience gradual evening of skin tone, reduction in dark spots, improved hydration, and a noticeable glow
Emerging Therapy Retatrutide Retatrutide is a new emerging (LY-3437943) is a triple-agonist peptide targeting GIP, GLP-1, and glucagon receptors currently under trial conducted by Eli Lilly and Company Mechanism of Action GIP agonism enhances insulin release, suppresses appetite, inhibits fat accumulation GLP-1 agonism enhances insulin release, suppresses glucagon, slows gastric emptying Glucagon receptor agonism boosts energy expenditure, supports glycemic control Collectively, it addresses glucose homeostasis, appetite regulation, energy metabolism, and weight loss Competitive Edge over Existing Therapies Superior efficacy: Around 24% weight loss surpasses GLP-1-only treatments (e.g., semaglutide, tirzepatide)
M.FinnellR
GLP-1 agonists are a type of medication often prescribed to manage type 2 diabetes alongside proper diet and exercise, without requiring insulin [3]
Nutrients 13(11):4014